The Efficacy of Oral Levofloxacin in the Treatment of Patient with Chronic Prostatitis.
- Author:
Chang Soo OH
1
;
Sang Hyeon CHEON
;
Ro Jung PARK
;
Mi Suk LEE
Author Information
1. Department of Urology, University of Ulsan College of Medicine, Ulsan, Korea. rjpark@uuh.ulsan.kr
- Publication Type:Original Article
- Keywords:
Chronic inflammatory prostatitis;
Levofloxacin;
Efficacy
- MeSH:
Follow-Up Studies;
Humans;
Leukocytes;
Levofloxacin*;
Prostatitis*
- From:
Infection and Chemotherapy
2005;37(2):99-103
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Antibiotic is widely used in the treatment of chronic prostatitis. In this study, we evaluated the clinical efficacy and safety of levofloxacin (Cravit(R)) in the treatment of patients with chronic prostatitis. MATERIALS AND METHODS: Between March 2001 and February 2003, 64 patients with chronic bacterial (NIH-category II) and nonbacterial inflammatory prostatitis (NIH-category IIIa) were enrolled in this study. Daily 400 mg of levofloxacin was administered orally for 4-18 weeks. To determine the efficacy of levofloxacin, patients were assessed with the NIH-CPSI and examined of expressed prostatic secretion (EPS) at 3 months follow-up period. RESULTS: The CPSI of 16 patients stratified into NIH-category II was 24.9+/-4.7 before and 14.1+/-6.5 after the treatment. For 48 patients stratified into NIH-category IIIa, the CPSI value before and after the treatment was 23.9+/-4.4 and 13.2+/-5.7, respectively. 40 patients (62.5%) showed mild to moderate improvement in NIH-CPSI, and 23 patients (35.9%) showed improvement in the laboratory profile according to the count of leukocytes (WBC <10/HPF) in EPS. Adverse reaction was noted in 1 patient during the treatment. Conclusions:This study shows that levofloxacin may be a safe and effective agent in treating either chronic bacterial prostatitis or chronic nonbacterial inflammatory prostatitis with few adverse reactions.
